Post by A*STAR - Agency for Science, Technology and Research

𝗛𝗼𝘄 𝗱𝗼 𝘄𝗲 𝗺𝗮𝗸𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝘀𝗶𝗺𝗽𝗹𝗲𝗿, 𝗺𝗼𝗿𝗲 𝗮𝗰𝗰𝗲𝘀𝘀𝗶𝗯𝗹𝗲 𝗮𝗻𝗱 𝗹𝗲𝘀𝘀 𝗶𝗻𝘃𝗮𝘀𝗶𝘃𝗲 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀? New findings from a study by A*STAR biotech spinoff Lucence, Singapore General Hospital and the DxD Hub - Diagnostics Development Hub, demonstrate the potential of urine-based liquid biopsy to strengthen the detection of bladder, prostate and kidney cancers. The test identified #cancer signals in over 90% of bladder cancer cases studied and showed promising results for prostate and kidney cancer detection. A key contribution from DxD Hub was the development of the diagnostic workflows needed to translate urine-based testing into a stable and clinically deployable solution, helping bridge the gap between scientific discovery and real-world healthcare application. More than a scientific advance, this work highlights how innovations at the intersection of MedTech and biotech can help make healthcare more precise — enabling earlier diagnosis, more personalised care and better outcomes for patients. #SGMedTech #InnovatewithASTAR #Healthinnovation